Gyorgy Horvath

Summary

Affiliation: Sahlgrenska University Hospital
Country: Sweden

Publications

  1. doi request reprint Different volatile signals emitted by human ovarian carcinoma and healthy tissue
    Gyorgy Horvath
    Sahlgrenska University Hospital, Goteborg, Sweden
    Future Oncol 6:1043-9. 2010
  2. doi request reprint Human ovarian carcinomas detected by specific odor
    Gyorgy Horvath
    Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden
    Integr Cancer Ther 7:76-80. 2008
  3. pmc Characteristic odour in the blood reveals ovarian carcinoma
    Gyorgy Horvath
    Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden
    BMC Cancer 10:643. 2010
  4. pmc External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
    Karolina Partheen
    Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
    BMC Cancer 9:336. 2009
  5. ncbi request reprint Identification of a gene expression signature for survival prediction in type I endometrial carcinoma
    Kristina Levan
    Department of Oncology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden
    Gene Expr 14:361-70. 2010
  6. pmc Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
    Lovisa Osterberg
    Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Sweden
    BMC Cancer 9:368. 2009
  7. ncbi request reprint Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas
    Lovisa Osterberg
    Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, SE 413 45 Goteborg, Sweden
    Anticancer Res 30:4451-8. 2010
  8. ncbi request reprint Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model
    Hakan Andersson
    Department of Oncology, Sahlgrenska University Hospital, Goteborg University, SE 413 45 Goteborg, Sweden
    Clin Cancer Res 9:3914S-21S. 2003
  9. doi request reprint Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up
    Margaretha Akeson
    Department of Oncology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    Acta Obstet Gynecol Scand 87:1343-52. 2008
  10. doi request reprint Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas
    Karolina Partheen
    Department of Oncology, University of Gothenburg, Gothenburg, Sweden
    Int J Cancer 123:2130-7. 2008

Collaborators

Detail Information

Publications18

  1. doi request reprint Different volatile signals emitted by human ovarian carcinoma and healthy tissue
    Gyorgy Horvath
    Sahlgrenska University Hospital, Goteborg, Sweden
    Future Oncol 6:1043-9. 2010
    ..Detection of different malignancies using canine scent, as well as other technical methods, has been reported in peer-reviewed journals, indicating that this may represent a new diagnostic tool for malignancies...
  2. doi request reprint Human ovarian carcinomas detected by specific odor
    Gyorgy Horvath
    Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden
    Integr Cancer Ther 7:76-80. 2008
    ..Our study strongly suggests that the most common ovarian carcinomas are characterized by a single specific odor...
  3. pmc Characteristic odour in the blood reveals ovarian carcinoma
    Gyorgy Horvath
    Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden
    BMC Cancer 10:643. 2010
    ..In a recently published study, we clearly demonstrated that human ovarian carcinoma tissues can be characterized by a specific odour, detectable by a trained dog. Another recent study confirmed these results using an electronic nose...
  4. pmc External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas
    Karolina Partheen
    Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden
    BMC Cancer 9:336. 2009
    ..We performed an external validation of the potential biomarkers CLU, ITGB3, CAPG, and PRAME to determine if the expression levels are relevant to use as prognostic factors...
  5. ncbi request reprint Identification of a gene expression signature for survival prediction in type I endometrial carcinoma
    Kristina Levan
    Department of Oncology, Sahlgrenska Hospital, Gothenburg University, Gothenburg, Sweden
    Gene Expr 14:361-70. 2010
    ....
  6. pmc Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas
    Lovisa Osterberg
    Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Sweden
    BMC Cancer 9:368. 2009
    ..The objective of this study was to explore genetic alterations behind chemotherapy resistance in ovarian cancer with the ultimate aim to find potential predictive markers...
  7. ncbi request reprint Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas
    Lovisa Osterberg
    Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, SE 413 45 Goteborg, Sweden
    Anticancer Res 30:4451-8. 2010
    ..Thus, finding predictive markers of chemoresistance and elucidating resistance mechanisms is crucial for individualising treatment and improving survival of ovarian cancer patients...
  8. ncbi request reprint Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model
    Hakan Andersson
    Department of Oncology, Sahlgrenska University Hospital, Goteborg University, SE 413 45 Goteborg, Sweden
    Clin Cancer Res 9:3914S-21S. 2003
    ..The aim of the study was to establish and refine a preclinical model to alpha-immunoradiotherapy of ovarian cancer...
  9. doi request reprint Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up
    Margaretha Akeson
    Department of Oncology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    Acta Obstet Gynecol Scand 87:1343-52. 2008
    ..To evaluate long-term survival and prognostic factors for all epithelial ovarian cancer (EOC) patients after adjuvant treatment with paclitaxel and carboplatin...
  10. doi request reprint Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas
    Karolina Partheen
    Department of Oncology, University of Gothenburg, Gothenburg, Sweden
    Int J Cancer 123:2130-7. 2008
    ..According to our results, the 4 biomarkers CLU, ITGB3, PRAME and CAPG may be used as prognostic factors for patients with stage III serous ovarian adenocarcinomas...
  11. ncbi request reprint Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas
    Lovisa Osterberg
    Department of Oncology, Sahlgrenska Academy, Goteborg University, Blå stråket 2, SE 413 45 Goteborg, Sweden
    Cancer Genet Cytogenet 167:103-8. 2006
    ....
  12. ncbi request reprint Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma
    Lovisa Osterberg
    Department of Oncology, Institute of Selected Clinical Sciences, Goteborg University, SE 413 45 Goteborg, Sweden
    Cancer Genet Cytogenet 163:144-50. 2005
    ..Our findings demonstrate biologic observations of clinical drug resistance and specifically reveal chromosomal regions of interest for platinum resistance...
  13. ncbi request reprint Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors
    Karolina Partheen
    Department of Oncology, Goteborg University, SE 413 45 Goteborg, Sweden
    Eur J Cancer 42:2846-54. 2006
    ..Alternative chemotherapy strategies could then be offered as first-line treatment, which may lead to improvements in the clinical outcome for these patients...
  14. doi request reprint A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors
    Margaretha Akeson
    Department of Oncology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    Int J Gynecol Cancer 19:116-23. 2009
    ....
  15. doi request reprint Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study
    Hakan Andersson
    Department of Oncology, University of Gothenburg, Gothenburg, Sweden
    J Nucl Med 50:1153-60. 2009
    ..The aim was to determine the pharmacokinetics for assessing absorbed dose to normal tissues and investigating toxicity...
  16. ncbi request reprint Function of the exon 7 deletion variant estrogen receptor alpha protein in an estradiol-resistant, tamoxifen-sensitive human endometrial adenocarcinoma grown in nude mice
    Gyorgy Horvath
    Gynecologic Oncology Section, Sahlgrenska University Hospital, Gothenburg, Sweden
    Gynecol Oncol 84:271-9. 2002
    ..In vitro studies suggest that exon deletion (Delta exon) variant forms of ER(alpha) may also play an important role in determining the progression from hormone dependence to hormone independence in receptor positive tumors...
  17. doi request reprint External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study--quality-of-life analysis
    Bengt Göran Sorbe
    Department of Gynecological Oncology, Orebro University Hospital, Orebro, Sweden
    Int J Gynecol Cancer 22:1281-8. 2012
    ..Quality-of-life analysis is an important part of a randomized study to find out the optimal adjuvant treatment for this group of patients...
  18. ncbi request reprint Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage
    Karolina Partheen
    Department of Oncology, Goteborg University, Goteborg, Sweden
    Genes Chromosomes Cancer 40:342-8. 2004
    ..On the basis of our results, we suggest that there are biological differences among the groups mentioned above and that absence of chromosomal aberrations in specific regions predicts a good clinical outcome for individual patients...